GlassScriptPhysician profile
Lukasz Niec
NPI 1124224183
$1,949.61
in general payments reported to CMS, 2019-2025
23 companies · $326 in 2025
The $326 reported for 2025 was more than what 85% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $185 · 2021: $207 · 2022: $66.82 · 2023: $367 · 2024: $240 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $369.10 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $265.30 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Novartis Pharmaceuticals Corporation | $243.89 | 2019-2025 | |
| Pfizer INC. | $174.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.02 | 2021-2024 | Jardiance |
| Melinta Therapeutics, LLC | $104.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $96.59 | 2019-2025 | Eliquis, Camzyos |
| Alexion Pharmaceuticals, INC. | $79.20 | 2023-2025 | Ultomiris, Soliris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.35 | 2019-2025 | Lifevest |
| Abbvie INC. | $53.75 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $46.93 | 2023-2025 | |
| Boston Scientific Corporation | $46.87 | 2022-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $44.53 | 2019-2020 | |
| Chiesi USA, INC. | $31.45 | 2021 | |
| Glaxosmithkline, LLC. | $29.15 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $25.56 | 2021 | |
| Csl Behring | $21.63 | 2025 | Kcentra |
| Mallinckrodt Enterprises LLC | $20.92 | 2019 | |
| Amgen INC. | $19.37 | 2020 | |
| Advanced Respiratory, INC | $19.17 | 2019 | |
| Vyera Pharmaceuticals, LLC | $17.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2023 | |
| Paratek Pharmaceuticals, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lukasz Niec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.